Catalent

Catalent, a US-headquartered pharmaceutical preparation manufacturing company, has actively reported its carbon emissions and set ambitious reduction targets.

In 2023, Catalent reported Scope 1 emissions of 106,900,000 kg CO2e and market-based Scope 2 emissions of 39,600,000 kg CO2e. For 2022, the company disclosed Scope 1 emissions of 114,600,000 kg CO2e, market-based Scope 2 emissions of 48,600,000 kg CO2e, and Scope 3 emissions totalling 718,400,000 kg CO2e. Key contributors to Scope 3 emissions in 2022 included purchased goods and services (498,800,000 kg CO2e), capital goods (94,000,000 kg CO2e), and employee commuting (45,400,000 kg CO2e).

Catalent has committed to significant emissions reductions validated by the Science Based Targets initiative (SBTi). The company aims to reduce absolute Scope 1 and 2 greenhouse gas emissions by 42% by fiscal year 2030 from a fiscal year 2022 base year. Additionally, Catalent commits to reducing absolute Scope 3 GHG emissions from fuel- and energy-related activities and employee commuting by 25% within the same timeframe. The company further pledges that 70% of its suppliers by emissions, covering purchased goods and services, capital goods, and upstream transportation and distribution, will have science-based targets by fiscal year 2028. Catalent's near-term targets for Scope 1 and 2 emissions are classified as consistent with keeping warming to 1.5°C. The company reported a 38% reduction in Scope 1 and Scope 2 carbon emissions from its fiscal 2020 baseline, indicating solid progress towards its 2030 target.